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Bupivacaine Toxicity Secondary to Continuous 
Cervical Epidural Infusion
Case Report
P. F. Baaijens, M.D.,* M. J. Gielen, M.D., Ph.D.,* T. B. Vree, Ph.D.,+ 
B. J. Crul, M.D., Ph.D,** and H. J. Jessen, M.D.*
Background and Objectives. A case is described of bupivacaine toxicity after c o n tin u ­
ous cervical epidural infusion in a pa tien t w ith  intractable cancer pain. The patien t 
had several periods of generalized tonic clonic seizures. Serial venous blood samples 
were taken after the first signs of toxicity, The highest to tal plasma bupivacaine level 
was 20.3 |ig/mL. The corresponding free bupivacaine concen tra tion  was no t d e te r­
mined. The highest m easured free bupivacaine concen tra tion  was 1.21 [ig/mL, co r­
responding with a total plasma bupivacaine level of 6,7 jug/mL. There w ere no signs 
of cardiovascular toxicity. The patien t recovered after trea tm en t w ithou t adverse 
sequelae. Methods. A plasma concen tra tion -tim e  curve w as constructed. There w as 
a rise in the plasma concentration of bupivacaine after th e  continuous infusion was 
stopped. Results. Total body clearance of bupivacaine was 20 m L /m in  and elim ina­
tion half-life was 27 hours. Conclusions. The case em phasizes the im portance of se r­
ial plasma concentrations of bupivacaine after con tinuous epidural infusion and the  
value of free bupivacaine concen tra tion  versus total bupivacaine concentration . Reg 
Anesth 1995:20:163-168.
Key words: bupivacaine, continuous cervical epidural infusion, systematic accum u­
lation, toxic effects, total body clearance.
There are some patients with cancer pain in 
whom pain control is very difficult, because som e  
pain syndromes may approach the nociceptive 
stimulation levels of surgical or postoperative pain. 
Therefore, the use of regional local anesthetics may  
be indicated.1
Case Report
A 51-year-old woman, weighing 50 kg, w ith a 
history of heavy smoking and high alcohol con-
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sumption, underw ent a partial mandibulectomy  
and neck dissection because of a squamous cell car­
cinoma of the left inferior processus alveolaris 
(TNM classification: T4N2bM0).
After the operation, there were no functional prob­
lems such as difficulty with speech or swallowing, 
and radiotherapy was started (total dose 64 Gy). 
Immediately after the radiation therapy was finished, 
the patient complained of severe pain in the neck on 
the operated and radiated side. There was profound 
spasticity on the left side of the neck, shoulder, and 
upper limb. There were no signs of recurrence of the 
primary tumor. Current medication consisted of 
oxazepam 50 mg, twice daily; temazepam 20 mg, 
once daily; and ranitidine 150 mg, twice daily.
Previous pain treatment included the use of sus­
tained release m orphine, coanalgesic therapy  
(acetam inophen, NSAID), benzodiazepines, and 
transcutaneous electric nerve stimulation (TENS).
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Failure to achieve acceptable pain relief and the 
uncontrollable side effects of morphine resulted in 
the choice of continuous cervical epidural infusion  
of bupivacaine for pain treatment.
A cervical epidural catheter was inserted at level 
C7-T1 using the paramedian approach (18-gauge 
Tuohy needle, hanging-drop technique). This level 
was chosen because it corresponded with the seg­
mental spinal cord level of maximal nociceptive 
pain stimulation. A bolus of 3 mL bupivacaine 
0.5% with epinephrine 1:200,000 was injected 
through the catheter. This resulted in a symmetric 
segmental sensory analgesia level of C3-T1 with  
only minimal motor block (grade I).2
The initial bolus was followed by a continuous 
epidural infusion of bupivacaine 0.75% without 
epinephrine at an infusion rate of 1,8 mL/h (13.5 
mg/h). With this regimen the patient was pain free 
(visual analog scale =  0), Respiratory rate, arterial 
pressure, and heart rate were stable. The patient 
was visited daily by an anesthesiologist. Six months 
before the operation, the patient had been treated 
in the same way with a lower dose (infusion rate of
1.0 mL/h, 7,5 mg/h), resulting in satisfactory anal­
gesia. After satisfactory analgesia was accomplished 
clinically, the patient returned home and was 
treated with continuous epidural infusion of bupi­
vacaine for 10 days using a Pharmacia Deltec 
CADD-PCA Pump (Pharmacia, Uppsala, Sweden).
On the evening of the third day, 53.5 hours after 
starting the continuous infusion of bupivacaine, the 
patient's condition deteriorated suddenly. The 
patient had tonic clonic seizures lasting about 1 
minute. The seizures were followed by increased 
lethargy. Her vital signs, including respiratory rate, 
arterial pressure, and heart rate, remained stable. 
There was no evidence of hypoxia or postictal apnea,
The epidural infusion of bupivacaine was stopped 
immediately. The position of the catheter was 
assessed by careful aspiration. There were no signs 
of intravenous or subarachnoid migration of the 
catheter tip. Sensory anesthesia was tested by pin­
prick and revealed a symmetric segmental sensory 
analgesia level of dermatomes C7-T2 with a bilat­
eral motor block (grade III)2 of the upper limbs. The 
patient received diazepam 10 mg rectally and no 
further seizures occurred. Electrolytes, calcium, 
magnesium, glucose and liver, and renal function 
tests were normal. The total plasma bupivacaine 
concentration was 10.7 fXg/mL,
At that time the patient had received 737 mg 
bupivacaine over 53.5 hours. Further bupivacaine 
venous blood samples were taken 2, 11, and 43 
hours after the first insult (Table 1). Oral carba- 
mazepine 200 mg, three times daily, and amitripty­
line 25 mg, once daily, were started for pain relief. 
Neurologic examination after the seizures revealed
no abnormalities.
Forty-two hours after the first insult, the continu­
ous infusion of bupivacaine was started again 
because the patient complained of unbearable pain 
and had suicidal thoughts. After a bolus of 3 mL 
bupivacaine 0.5% with epinephrine 1:200,000 was 
administered, a continuous infusion of bupivacaine
0.75% without epinephrine was started at an infu­
sion rate of 1.0 mL/h (7.5 m g/h). This resulted in a 
sensory analgesia level of dermatomes C3-T4 with 
good pain relief. Twenty-one hours later, the patient 
again had a tonic clonic seizure after an infusion of 
172 mg bupivacaine over that period. The infusion 
of bupivacaine was stopped and the catheter tip 
position reassessed. The patient was treated in the 
same way with diazepam 10 mg rectally and clon­
azepam 0.5 mg intramuscular twice daily. Venous 
blood samples were taken immediately after the 
insult and 9, 21, 45, and 69 hours later (Table 1). A 
computer tomography scan of the cerebrum was 
normal and showed no metastatic lesions.
After the second insult, the patient had three 
more periods with seizures. An ECG was done each 
time but showed no abnormalities. Two times she 
fell while she was on her way to the bathroom. The 
patient reported no prodromal signs usually seen 
with acute systemic toxicity of local anesthetics. 
The cervical epidural catheter was removed. Block 
of the cervical nerves C2-3 was achieved with local 
anesthetic injections; this clearly reduced the pain 
and the patient was allowed to return hom e.
Materials and Methods
Bupivacaine analysis was performed using the 
high-performance liquid chromatography (HPLC) 
method as described.3
Reagents and Materials
Bupivacaine HC1 (Astra Pharmaceutics, Rijswijk, 
The Netherlands) was used for the epidural infu­
sion. Solvents were of HPLC grade. A stock solution 
of 200 mg/L was prepared in 100% methanol. Drug 
plasma standards were prepared by spiking blank 
control plasma with appropriate microliter volumes 
of working drug solution. Six plasma standards 
were obtained with the following concentrations of 
bupivacaine: 0.25, 1.0, 2.0, 4.0, 10.0, and 25 jdg/mL
Preparation of the Samples
Twenty micrograms of bupivacaine in 180 (iL of 
blank plasma or 200 ¡ig sample plasma and 200 |LLg
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Table 1. U nbound  and Total Plasma B upivacaine C oncen tra tions in a P a tien t R eceiving C o n tin u o u s  Cervical
E p id u ra l B upivacaine  In fu s io n
Hours A fter Total T ota l A m o u n t
Starting th e P la sm a Free o f  I n fu s e d
C on tin u ou s B u p iv a ca in e B u p iv a ca in e B o u n d B u p iv a c a in e C lin ica l I n f u s io n  R a te
Infusion (|ig /m L ) (fig/m L) (%) (nmg) P r e s e n ta t io n (m g /h )
53.5 10.7 Not determined 737.25 Seizures 13.5
55.5 20.3 Not determined 0
66.5 17.7 Not determined 0
97 8.3 0.80 90 After 109.5 h 
infusion was  
restarted at rate 7.5
114.5 4.3 0.80 81 172.5 Seizures 0
123.5 5.3 1.12 79 Seizures 0
136 6.7 1.21 82 Seizures 0
160 5.1 0.66 87 0
184 3.2 0.75 77 0
Average protein binding, 85% (±5%).
trichloroacetic acid were placed into a 1.5 mL 
Eppendorf tube (Eppendorf, Hamburg, Germany). 
After mixing and centrifuging at 12,500g for 4 m in­
utes, 100 |llL of the supernatant was injected onto  
the column.
High-performance Liquid Chromatography
The analysis was performed using a 740 solvent 
delivery system (Spectra Physics, Eindhoven, The 
Netherlands), a BD 40 recorder (Kipp Analytica, 
Delft, The Netherlands), an N 60 injector (Valeo H, 
Chrompack, Middelburg, The Netherlands), a 
Spherisorb 5 ODS column (250 X 4.6 mm; 
Chrompack), and a Spectroflow 757 variable w ave­
length absorbance detector (Separations, H.I. 
Ambacht, The Netherlands). D etection was 
achieved at 217 nm. The mobile phase consisted, of 
phosphoric acid 0.006 M, acetonitrile (65:35  
vol/vol) and tetramethylammoniumchloride 0.750  
g/L. The flow rate was 1.2 mL/minute. The reten­
tion time of bupivacaine is 13.0 minutes.
Free Bupivacaine Concentration
For determination of free bupivacaine concentra­
tion the Amicon Micropartition System (MPS-1, 
Amicon Division, Capelle a/d IJsel, The Netherlands) 
was used. Based on the unique equilibrium nature 
of ultra filtration partition, it is intended for separa­
tion of free from protein bound microsolute in small 
volumes of serum, plasma, or other biological fluids 
at physiological pH of 7.4. Separation of free from 
protein bound microsolute is provided by convective 
filtration of free microsolute through an anisotropic, 
hydrophilic YMT ultrafiltration membrane. The dri­
ving force for filtration is provided by centrifugation 
during 15 minutes at 1,000-2,000 X g, achieving 
transmembrane pressures of up to 106 psi (7.2 atm).
Use of a fixed-angle rotor provides polarization con­
trol, minimizing the potential for nonideal pro- 
tein-protein interactions. The ultrafiltrate can then 
be analyzed for free microsolute fraction or concen­
tration. The procedure is performed at room  
temperature.
Validation
The calibration curves were constructed by plot­
ting the peak height ratios against known concen­
trations of bupivacaine* Standard curves were con­
structed by least-square regression for calculation 
of unknow n concentrations. Interday variation is 
8% CV (coefficient of variance) at 0.5 |Ug/mL and
1.5% CV at 4 .0  |itg/mL. Interday variation is 9.7% 
CV at 0.5 jig/mL, 4.6% CV at 1.0 |Ltg/mL, 5.0% at
2.0 ixg/mL, and 3.1% CV at 4.0 |Hg/mL.
Results
Systemic toxicity of bupivacaine with a total plas­
ma level of 20.3 jag/mL w ithout signs of cardiovas­
cular toxicity has never been reported. The plasma 
concentration-time curve of our patient is show n in 
Figure 1. The total bupivacaine and free bupiva­
caine levels are listed in Table 1.
With the data from Table 1 and assuming a 
steady-state concentration (Css) of 10.7 |.ig/mL, the 
total body clearance can be calculated. The total 
body clearance is equal to the rate of infusion (Ro) 
divided by the steady-state plasma concentration.3“6 
The clearance of bupivacaine at the time of the first 
convulsion is 20 mL/min, which is extremely low. 
The calculated elimination half-life is 27 hours, 
which corresponds with an extremely low clear­
ance. The sample taken at 53 hours is approximate­
ly 75% of the expected steady-state value and the
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Time curve
Mg m l 1
t Seizures
Time (hours)
Fig. 1 Bupivacaine plasma concentration
calculated clearance is therefore overestimated. 
Because of the highly varying plasma concentration  
and the re-entering drug dose, it is nearly im possi­
ble to properly calculate the clearance.
When the continuous infusion in our patient was 
stopped the second time, the total bupivacaine con ­
centration was 4.3 jig/mL, and the free bupivacaine 
concentration was 0.80 |ag/mL. The clinical presen­
tation was a generalized tonic clonic convulsion. 
The patient had two more convulsions, correspond­
ing with total bupivacaine levels of 5.3 (xg/mL and  
6.7 [ig/mL and free bupivacaine levels of 1.12  
|ig/mL and 1,21 jiig/mL. W hen the patient had a 
total plasma level of 8.3 (xg/mL (at t =  97 hours) 
with a free bupivacaine level of 0.80 (ig/mL, there 
were no convulsions.
Discussion
Continuous infusion of local anesthetics through  
the epidural route has gained popularity for  
the treatment of intractable cancer pain w h en  
opioids alone do not give sufficient pain relief.1 
Bupivacaine is the local anesthetic chosen because  
of its longer duration of action and greater sensory  
versus m otor block.7 A potential problem w ith con ­
tinuous epidural infusion of a local anesthetic agent
is accumulation, which may lead to systemic toxic 
effects.6^ 8
Following rapid bupivacaine infusion, the major­
ity of reported central nervous symptoms occurred 
between plasma concentrations of 2 and 4 [ig/mL 
(total bupivacaine)6'8 and 0.24 |ig/mL (free bupiva­
caine).9 There is evidence that the toxic effects are 
likely to be more closely related to free unbound  
plasma concentration than total blood or plasma 
concentration.1'4'8 Current understanding of local 
anesthetic toxicity is limited to experience with sin ­
gle-dose techniques associated with operative or 
obstetric analgesia, case reports, and animal stud­
ies.1 Patients receiving infusions of bupivacaine 
may be at increased risk of developing systemic 
toxicity because of the high plasma concentra­
tion.4'6*8'10'11 A rapid initial absorption phase is 
followed by a much slower phase. The initial 
absorption occurs predominantly by uptake into  
blood vessels from the dense venous plexus w ithin  
the epidural space, resulting in a high absorption 
rate and peak concentration. The late absorption 
phase is due to slow uptake of bupivacaine in  
epidural fat. This epidural fat can serve as a depot 
for local anesthetics, in particular for the more 
liphophilic agents such as bupivacaine. Continuous 
infusion of this agent results in a rise of epidural fat
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concentration followed by a subsequent slow  
release and resulting longer half-life.6
A study of chronic epidural bupivacaine infusions 
in a population of advanced cancer patients showed  
asymptomatic patients with total bupivacaine con ­
centrations of 4-5  (Xg/mL up to concentrations as 
high as 10.8 ¡xg/mL (total bupivacaine) and 1.01 
jxg/mL (free bupivacaine),1 There was considerable 
inter- and intraindividual variability in plasma 
bupivacaine concentrations and bupivacaine clear­
ance.1 Some patients exhibited relative stability of 
plasma clearance and plasma bupivacaine concen­
trations during the monitoring period; in other 
patients there was an increase in plasma bupiva­
caine concentrations.1 The calculated total body 
clearance in these patients was lower.
It is remarkable that after stopping the continu­
ous epidural infusion in this patient, the total 
plasma level of bupivacaine still rose from 10.7 
|xg/mLto 20.3 |xg/mL (unfortunately, the free bupi­
vacaine levels of these samples were not deter­
mined). A continuous release ol bupivacaine from 
the epidural fat depot after stopping the infusion is 
unlikely to be the cause. Blood concentrations arise 
from input of the drug in the epidural space and 
subsequent redistribution between the plasma com ­
partment and the peripheral compartments.6,12,13 In 
the case of bupivacaine, this results in at least three 
input functions into and out of the central com ­
partment. When drug delivery, namely, the epidur­
al infusion, is stopped, it is difficult to understand 
how the remaining input functions can result in a 
blood concentration twice that obtained with the 
epidural infusion in progress, An alternative expla­
nation for this finding is that bupivacaine was 
trapped in the stomach and a large amount reen­
tered the circulation after gastric em ptying  
occurred.14 Previous investigations have shown  
that weak bases will cross the plasmagastric barrier 
and become concentrated in acid gastric juice. 
Weak bases will ionize to a greater degree in an acid 
medium than in a base or neutral environm ent.14 
Ionized molecules in the gastric fluid are trapped 
within the gastric compartment. Bupivacaine is a 
weak base (pKa 8 .1 ).15 This mechanism is also pre­
scribed for lidocaine (pKa 7.8) after epidural anal­
gesia for vaginal delivery,14 There was a significant 
inverse correlation between gastric pH and gastric 
lidocaine concentration of the neonate.14 We sug­
gest that gastric lavage is a beneficial treatment for 
neonatal lidocaine intoxication in these patients.14 
Whether this is the case after prolonged epidural 
infusion in cancer patients needs further investiga­
tion. Gastric lavage should be considered as a treat­
ment after bupivacaine intoxication.
Bupivacaine in hum an plasma is bound to two 
types of sites: a low-affinity, high-capacity site 
(albumin) and a high-affinity, low-capacity site 
(alpha acid glycoprotein, AAG).16 With elevated 
AAG, w hich is particularly the case in cancer 
patients, higher than normal Css for a given Ro are 
found..6'13,16'17 Increases in AAG increase protein- 
binding, lowering the fraction of free drug and thus 
decreasing the CL A decrease in Cl could produce a 
higher incidence of systemic toxicity.16 This was not 
observed in several studies and may be due to 
increased protein binding of bupivacaine to 
AAG.16,17 Also, factors other than free versus total 
bupivacaine concentrations m ay exist to explain 
the relative resistance of cancer patients to bupiva­
caine toxicity.1
The plasma drug concentrations of this patient 
are difficult to explain. It is well documented that 
the plasma-bound proportion of local anesthetic is 
inversely related to the drug's plasma level.12 The 
higher the plasma level of anesthetic, the more 
plasma receptors approach saturation, and the 
fewer binding sites remain unoccupied.12 The aver­
age protein binding of this patient was 85% (±5% , 
Table 1), a percentage also found by others.1 
Normally the plasma binding of bupivacaine is 
96% .6,15 Our patient had a normal albumin con­
centration of 45 g/L, so the lower binding was not 
caused by decreased protein.17 The lower plasma 
binding of bupivacaine in our patient can be 
explained by the saturation or loss of binding sites 
or conformational changes.12
The patient had seizures at a number of low total 
bupivacaine concentrations but did not have  
seizures at other higher concentrations. This can be 
explained by a rapid rise in bupivacaine level after 
starting the infusion. The rate of increase in plasma 
concentration is more important than any exact 
concentration for developing system ic toxicity  
sym ptom s.6 Plasma concentrations of lidocaine 
injected into the cervical, thoracic, and lumbar 
epidural spaces are similar, so it appears that there 
is no difference in the rate of vascular absorption of 
lidocaine from different parts of the epidural space. 
However, there are no studies of plasma concentra­
tions obtained during cervical epidural anesthesia 
using continuous catheter techniques.18
By infusing a combination of bupivacaine-opioid, 
a lower concentration of bupivacaine can be used, 
thus reducing the risk of toxicity, w ithout affecting 
analgesia 4 Further studies are needed to elucidate 
the m echanism  of altered bupivacaine kinetics dur­
ing prolonged epidural infusion of bupivacaine in 
cancer patients.1,13
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